跳至主要内容
临床试验/ACTRN12614000154606
ACTRN12614000154606尚未招募3 期

In patients with congestive heart failure and iron deficiency, can iron replacement improve symptoms of heart failure?

Haematology Department, Fremantle Hospital0 个研究点目标入组 30 人开始时间: 2014年2月10日最近更新:
适应症

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • 1. Male or female 18 years of age or above
  • 2. Congestive heart failure of New York Heart Association (NYHA) functional class II or III, defined by left ventricular ejection fraction of 40% or less (for patients with NYHA class II) or 45% or less (for NYHA class III)
  • 3. Iron deficiency, defined by ferritin level <100 microg per liter or between 100 and 299 microg per liter, if the transferrin saturation is <20%
  • 4. Haemoglobin level at the screening less than 135 g per liter
  • 5. Written informed consent

排除标准

  • 1. Acute Heart Failure
  • 2. Clinically significant Chronic Obstructive Pulmonary Disease, defined as moderate or worse on GOLD grading
  • 3. Clinically significant liver impairment, defined as Child-Pugh class B or C
  • 4. Clinically significant renal impairment, defined as Chronic Kidney Disease stage 5
  • 5. Presence of other condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data

研究者

发起方
Haematology Department, Fremantle Hospital

相似试验